Free-Reprint Article Written by: Norm Howe See Terms of Reprint Below.
***************************************************************** * * This email is being delivered directly to members of the group: * * [email protected] * ***************************************************************** We have moved our TERMS OF REPRINT to the end of the article. Be certain to read our TERMS OF REPRINT and honor our TERMS OF REPRINT when you use this article. Thank you. This article has been distributed by: http://Article-Distribution.com Helpful Link: The Digital Millennium Copyright Act - Overview http://www.gseis.ucla.edu/iclp/dmca1.htm --------------------------------------------------------------------- Article Title: ============== The Evolution of Process Validation Article Description: ==================== In November 2008, the U.S. Food and Drug Administration (FDA) published draft guidance on process validation. Entitled Process Validation: General Principles and Practices, this draft guidance replaces the previous guidance issued in 1987. What does this mean to you? Additional Article Information: =============================== 471 Words; formatted to 65 Characters per Line Distribution Date and Time: 2009-01-27 12:48:00 Written By: Norm Howe Copyright: 2009 Contact Email: mailto:[email protected] For more free-reprint articles by Norm Howe, please visit: http://www.thePhantomWriters.com/recent/author/norm-howe.html ============================================= Special Notice For Publishers and Webmasters: ============================================= If you use this article on your website or in your ezine, We Want To Know About It. Use the following URL to let us know where you have used this article, and we will include a link to your website on thePhantomWriters.com: http://thephantomwriters.com/notify.php?id=6515&p=load HTML Copy-and-Paste and TEXT Copy-and-Paste Versions Of Article Are Available at: http://thePhantomWriters.com/free_content/db/h/evolution-of-process-validation.shtml#get_code --------------------------------------------------------------------- The Evolution of Process Validation Copyright (c) 2009 Norm Howe Validation and Compliance Institute http://www.vcillc.com In November 2008, the U.S. Food and Drug Administration (FDA) published draft guidance on process validation. Entitled Process Validation: General Principles and Practices, this draft guidance replaces the previous guidance issued in 1987. The new draft guidance, which is consistent with the goals outlined in FDAs initiative Pharmaceutical CGMPs for the 21st Century - A Risk-Based Approach, incorporates modern risk management and quality systems tools and concepts. It also addresses product life cycle issues, such as process design, process qualification, and continued process verification. The draft guidance is also aligned with International Conference on Harmonization quality guidance documents, including Q8: Pharmaceutical Development, Q9: Quality Risk Management, and Q10: Pharmaceutical Quality System. The draft introduces a new definition of process validation as "the collection and evaluation of data, from the process design stage through production, which establishes scientific evidence that a process is capable of consistently delivering quality products." Moreover, process validation is split up into three stages: "Process Design," or the commercial process that is based on experiences gained from development and scale-up; "Process Qualification," or when the reproducible, commercial scale is confirmed on the basis of process design; and "Continued Process Verification," which is meant to show that the process is in a state of control during routine production. According to the draft, A successful validation program depends upon information and knowledge from product and process development. This knowledge and understanding is the basis for establishing an approach to control that is appropriate for the manufacturing process. Within the document, manufacturers are recommended to understand the sources of variation; detect the presence and degree of variation; understand the impact of variation on the process and ultimately on product attributes; and control the variation in a manner commensurate with the risk it represents to the process and product. The draft further recommends an integrated team approach to process validation that includes expertise from a variety of disciplines, including process engineering, industrial pharmacy, analytical chemistry, microbiology, statistics, manufacturing, and quality assurance. Manufacturers should also note that the draft states, However, it is not a regulatory expectation that the process be developed and tested until it fails, but rather that a process be controlled within commercial manufacturing conditions, including those combinations of conditions posing a high risk of process failure. The draft guidance applies to process validation of human and animal drug and biological products, including active pharmaceutical ingredients (API or drug substance). The following categories of products are not covered: Type A medicated articles and medicated feed; medical devices; dietary supplements; and human tissues intended for transplantation regulated under section 361 of the Public Health Service Act. The draft is 20 pages divided into seven chapters: Introduction; Background; Statutory and Regulatory Requirements for Process Validation; Recommendations; Concurrent Release for Performance Qualification Batches; Documentation; and Analytical Methodology. Read the full draft here: http://www.fda.gov/CDER/GUIDANCE/8019dft.pdf --------------------------------------------------------------------- Norm Howe, Senior Partner at Validation and Compliance Institute, consultants for the pharmaceutical and medical device industries. He got his BS at UC, Berkeley, and a Ph.D. in chemistry at UCLA. He has held many management positions in FDA regulated industries, most at BASF. http://www.vcillc.com --- END ARTICLE --- Get HTML or TEXT Copy-and-Paste Versions Of This Article at: http://thePhantomWriters.com/free_content/db/h/evolution-of-process-validation.shtml#get_code ..................................... TERMS OF REPRINT - Publication Rules (Last Updated: May 11, 2006) Our TERMS OF REPRINT are fully enforcable under the terms of: The Digital Millennium Copyright Act http://thomas.loc.gov/cgi-bin/query/z?c105:H.R.2281.ENR: ..................................... *** Digital Reprint Rights *** * If you publish this article in a website/forum/blog, You Must Set All URL's or Mailto Addresses in the body of the article AND in the Author's Resource Box as Hyperlinks (clickable links). * Links must remain in the form that we published them. Clean links should point to the Author's links without redirects having been inserted into the copy. * You are not allowed to Change or Delete any Words or Links in the Article or Resource Box. Paragraph breaks must be retained with articles. You can change where the paragraph breaks fall, but you cannot eliminate all paragraph breaks as some have chosen to do. * Email Distribution of this article Must be done through Opt-in Email Only. No Unsolicited Commercial Email. * You Are Allowed to format the layout of the article for proper display of the article in your website or in your ezine, so long as you can maintain the author's interests within the article. * You may not use sentences from this article as an input for any software that steals sentences from others in order to build an article with software. The copyright on this article applies to the "WHOLE" article. *** Author Notification *** We ask that you notify the author of publication of his or her work. Norm Howe can be reached at: [email protected] *** Print Publication Reprint Rights *** If you desire to publish this article in a PRINT publication, you must contact the author directly for Print Permission at: mailto:[email protected] ..................................... If you need help converting this text article for proper hyperlinked placement in your webpage, please use this free tool: http://thephantomwriters.com/link-builder.pl ===================================================================== ABOUT THIS ARTICLE SUBMISSION http://thePhantomWriters.com is a paid article distribution service. thePhantomWriters.com and Article-Distribution.com are owned and operated by Bill Platt of Stillwater, Oklahoma USA. Learn more about our article distribution services by visiting: http://thephantomwriters.com/x.pl/tpw/info/article-distribution/index.html The content of this article is solely the property and opinion of its author, Norm Howe http://www.vcillc.com --------------------------------------------------------------------- XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX --------------------------------------------------------------------- ------------------------------------ *-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-* To have your article appear in this distribution list, you must absolutely be a client of thePhantomWriters. We offer a paid article distribution service, and this is one of the more than 60 groups where we submit our client articles. To learn more about our program, visit: http://thePhantomWriters.com/x.pl/tpw/index.htmYahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/thePhantomWriters/ <*> Your email settings: Individual Email | Traditional <*> To change settings online go to: http://groups.yahoo.com/group/thePhantomWriters/join (Yahoo! ID required) <*> To change settings via email: mailto:[email protected] mailto:[email protected] <*> To unsubscribe from this group, send an email to: [email protected] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/
